Qing Z, Sandor M, Radvany Z, Sewell D, Falus A, Potthoff D, Muller W A, Fabry Z
Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, 53706, USA.
J Neuropathol Exp Neurol. 2001 Aug;60(8):798-807. doi: 10.1093/jnen/60.8.798.
Trafficking of antigen-specific T cells into the central nervous system (CNS) is an important initiating step in inflammation in the brain. In spite of the extensive knowledge about the role of adhesion molecules in T cell migration across peripheral vessels, the mechanism of the entry of antigen-specific T cells into the CNS is not known. This work was designed to study the regulatory roles of adhesion molecules in antigen-specific T cell migration into the CNS. Antigen-specific T cells were tracked in an in vivo migration assay using T cell receptor (TCR) transgenic mice having 95% of T cells specific for a defined antigen. pigeon cytochrome c (PCC). TCR transgenic mice were cannulated intraventricularly (IVT) for PCC antigen infusion and cerebrospinal fluid (CSF) sampling. Upon PCC infusion into the CNS, the number of alpha/beta TCR+ Vbeta3+ Mac1- cells in the CSF was characterized in the presence or absence of anti-adhesion molecule reagents. We found that antibodies against VCAM-1 (CD106), VLA-4 (CD49d/CD29), ICAM-1 (CD54), and LFA-1 (CD11a/CD18) did not influence the increased number of antigen-specific T cells in the CSF However, upon intravenous (i.v.) injection, anti-PECAM-1 (CD31) antibody or PECAM-Ig chimeric molecule inhibited the trafficking of alpha/beta TCR+ Vbeta3+ Mac1- cells into the CNS. The expression of PECAM-1 (CD31) was also up-regulated on antigen-specific T cells in a time-dependent manner in vitro upon antigenic stimulation. The antigen-induced activation of T cells in vivo was measured by CD44 and LFA-1 expression and found to be comparable between mPECAMIg-treated mice and wild-type serum control-treated groups. This indicates that CD31 inhibition of antigen-specific T cell accumulation in the CNS is probably not due to a functional inhibition of these cells. Finally, adoptive transfer of CFSE-labeled AND transgenic cells into naïve animals resulted in the accumulation of these cells in the CNS upon PCC IVT immunization that was also inhibited by mPECAMIg treatment. Hence, PECAM-1 (CD31) might play an important role in regulating antigen-specific T cells trafficking in CNS inflammatory diseases.
抗原特异性T细胞向中枢神经系统(CNS)的转运是脑部炎症的一个重要起始步骤。尽管人们对抗黏附分子在T细胞跨外周血管迁移中的作用已有广泛了解,但抗原特异性T细胞进入CNS的机制尚不清楚。本研究旨在探讨黏附分子在抗原特异性T细胞向CNS迁移中的调节作用。在体内迁移试验中,使用T细胞受体(TCR)转基因小鼠追踪抗原特异性T细胞,这些小鼠95%的T细胞对特定抗原——鸽细胞色素c(PCC)具有特异性。TCR转基因小鼠通过脑室内插管(IVT)进行PCC抗原输注和脑脊液(CSF)采样。在向CNS输注PCC后,在有或没有抗黏附分子试剂的情况下,对CSF中α/β TCR + Vβ3 + Mac1-细胞的数量进行了表征。我们发现,针对血管细胞黏附分子-1(VCAM-1,CD106)、迟现抗原-4(VLA-4,CD49d/CD29)、细胞间黏附分子-1(ICAM-1,CD54)和淋巴细胞功能相关抗原-1(LFA-1,CD11a/CD18)的抗体,并不影响CSF中抗原特异性T细胞数量的增加。然而,静脉内(i.v.)注射时,抗血小板内皮细胞黏附分子-1(PECAM-1,CD31)抗体或PECAM-Ig嵌合分子可抑制α/β TCR + Vβ3 + Mac1-细胞向CNS的转运。在体外,抗原刺激后,PECAM-1(CD31)在抗原特异性T细胞上的表达也呈时间依赖性上调。通过CD44和LFA-1表达来检测体内T细胞的抗原诱导活化,发现mPECAMIg处理的小鼠与野生型血清对照处理组之间具有可比性。这表明CD31对CNS中抗原特异性T细胞积累的抑制作用可能并非由于对这些细胞的功能抑制。最后,将羧基荧光素二醋酸盐琥珀酰亚胺酯(CFSE)标记的AND转基因细胞过继转移到未免疫动物体内,在PCC IVT免疫后,这些细胞在CNS中积累,而mPECAMIg处理也可抑制这种积累。因此,PECAM-1(CD31)可能在调节CNS炎症性疾病中抗原特异性T细胞的转运方面发挥重要作用。